Results 131 to 140 of about 39,064 (303)
Health technology assessment of biosimilars worldwide: a scoping review
Health Research Policy and Systems, 2020 Background Health technology assessment (HTA) should provide an assessment of a technology’s effects on health and of the related social, economic, organisational and ethical issues. HTA reports on biosimilars can specifically assess their immunogenicity,
Bruna de Oliveira Ascef +2 more
doaj +1 more source
Small Structures, EarlyView.The constant fragment (Fc) of the immunoglobulin G1 (IgG1) subtype is a widely used scaffold for designing advanced therapeutics. Herein, together with the integration of experimental and computational techniques, this study reveals the structural dynamics of the N‐glycan‐bound Fc fragment of IgG1 from VEGF‐Trap, providing a new insight into enhancing ...
Ebru Destan +11 more
wiley +1 more source
Bioethical issues in the development of biopharmaceuticals [PDF]
, 2012 Development of biopharmaceuticals is a challenging issue in bioethics. Unlike conventional, small molecular weight drugs, biopharmaceuticals are proteins derived from DNA technology and hybrid techniques with complex three dimensional structures ...
Protić Dragana, Todorović Zoran
core +1 more source
Global Inflammatory Bowel Disease: Opportunities and Challenges for a New Era
United European Gastroenterology Journal, EarlyView.ABSTRACT Inflammatory Bowel Disease (IBD) has become a global disease. The increasing incidence of inflammatory bowel disease across the world is challenging the traditional view of IBD as a western disease and represents a unique opportunity to gain an understanding of the disease in diverse ethnic groups and in different socio‐economical and ...
Ignacio Catalan‐Serra, Shaji Sebastian
wiley +1 more source
Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge
European Medical Journal Rheumatology, 2018 Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo +2 more
doaj
Health Services Research, EarlyView.ABSTRACT Objective To estimate the impact of state‐level insulin out‐of‐pocket caps on changes in out‐of‐pocket and total costs of insulin and healthcare for insulin users with employer‐sponsored insurance. Study Setting and Design We evaluated changes in costs using a quasi‐experimental (triple difference‐in‐differences; “DDD”) design to analyze multi‐
Khrysta A. Baig +4 more
wiley +1 more source
Factors that Influence Healthcare Professionals' Intentions towards Biosimilars
INNOVATIONS in PharmacyBackground: Physicians often prescribe original biologic products to patients who have not used them before and are reluctant to switch to biosimilars.
Mohammed Alqahtani +2 more
doaj +1 more source
Allergy, EarlyView.This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini +16 more
wiley +1 more source
Pharmacogenetics of follicle‐stimulating hormone action in the male
Andrology, EarlyView.Abstract Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle‐stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism.
Andrea Graziani +7 more
wiley +1 more source